

6. (Amended). A capsule formulation comprising an anti-hypertensive, anti-ischaemic or angina - alleviating effective amount of the besylate salt of amlodipine as claimed in claim 1 in admixture with excipients.

8. (Amended). A capsule formulation as claimed in claim [1] 7 wherein the excipients comprise microcrystalline cellulose, dried maize starch and magnesium stearate.

9. (Amended). A sterile aqueous solution comprising an antihypertensive, anti-ischaemic or angina - alleviating effective amount of the besylate salt of amlodipine for parenteral administration.

Cancel claim 12.

R E M A R K S

The composition claims have been amended to recite the amount of active ingredient in functional language.

Claim 12, a product claim drafted in terms of use, has been cancelled.

The Examiner is correct in that the subject matter of the various claims was commonly owned at the time the invention was made.

Concerning the rejection under 35 U.S.C. 103, both the ancillary references of Schmidt, et al. and Spiegel, et al., teach compounds of structures and uses apart from those of the instant application. Schmidt teaches the increase in solubility of acid addition salts of bases when the acids are derived from a wide variety of sulfonic acids. Spiegel merely identifies the besylate salt as the preferred salt of a phenothiazine, sleep-promoting agent, without any reason for its choice.


As pointed out in the various tables of the present application the besylate salt, contrary to the findings of Schmidt, while not the most soluble salt, has many other advantages not possessed by other acid addition salts, and

certainly not suggested by either of the cited Schmidt and Spiegel references.

The besylate salt, in addition to having good solubility, is also unique in imparting to the product good stability, nonhygroscopicity and good processability. For one salt to have all these outstanding features is not suggested or taught in the art, and would require extensive experimentation to find.

Applicants respectfully request a reconsideration of the rejected claims in the light of the above amendment and arguments.

Respectfully submitted,


James M. McManus
Agent for Applicants
Reg. No. 28,642
Tel.: (203) 441-4903

Date: March 3, 1988

Enclosure

P0093834

P0093834